Patent · US Active

Methods of treatment using anti-GM-CSF antibodies

US10377820B2 · kind B2 · utility

0Cited by

6References

8Claims

0Family size

Assignee

MORPHOSYS AG · DE

Inventors

Stefan Steidl · Munich, DE
Elisabeth Thomassen-Wolf · Birkenfeld, DE

Key dates

Filing date	Dec 21, 2016
Grant date	Aug 13, 2019
Priority date	—
Expiry date	Dec 21, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides recombinant antigen-binding regions, antibodies and functional fragments thereof that are specific for GM-CSF, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, inflammatory diseases such as rheumatoid arthritis. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of GM-CSF in the progression of various disorders. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.